Annual report pursuant to Section 13 and 15(d)

Related Party Transactions (Details)

v2.4.0.6
Related Party Transactions (Details) (USD $)
Share data in Thousands, unless otherwise specified
12 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Maxygen [Member]
Dec. 31, 2010
Maxygen [Member]
Dec. 31, 2011
Maxygen [Member]
Oct. 31, 2010
Maxygen [Member]
Nov. 30, 2007
Shell [Member]
Dec. 31, 2012
Shell [Member]
Dec. 31, 2011
Shell [Member]
Dec. 31, 2010
Shell [Member]
Dec. 31, 2012
Raizen [Member]
Jun. 30, 2011
Raizen [Member]
Dec. 31, 2012
Exela PharmaSci, Inc [Member]
Dec. 31, 2011
Exela PharmaSci, Inc [Member]
Dec. 31, 2012
Maxygen intellectual property [Member]
Dec. 31, 2011
Maxygen intellectual property [Member]
Oct. 31, 2010
Maxygen intellectual property [Member]
Maxygen [Member]
Related Party Transaction [Line Items]                                  
Net consideration transferred           $ 20,200,000                      
Cash paid for acquisition           20,000,000                      
Transaction costs           700,000                      
Extinguishment of royalty payable           500,000                      
Intangible asset 24,876,000 24,876,000                         20,244,000 20,244,000 20,200,000
Due to Maxygen     0 170,000 0                        
Maximum reimbursement of expenses (percent)     20.00%                            
Expenses from transactions with Maxygen       1,200,000                          
Shells percentage of total Collaborative R&D revenue (percent)               51.00% 51.00% 62.00%              
Shares held by collaboration company (shares) 37,692 35,996                   5,600          
Material financial activity                     0            
Revenue from exclusivity fee             20,000,000           150,000 450,000      
Amounts owed                         $ 0 $ 0